# IDRx

Source: https://onco.cc/companies/idrx/  
OnCo record `idrx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IDRx, a Boston company, developed IDRX-42, a pill aimed at the KIT gene changes that drive most gastrointestinal stromal tumours (GIST). GSK bought the company in 2025.

## Summary

IDRx, Inc. was a Boston-based, clinical-stage company developing precision treatments for gastrointestinal stromal tumours. Its lead molecule, IDRX-42, is a highly selective KIT tyrosine kinase inhibitor being developed for first- and second-line treatment; GSK's announcement says about 80% of GIST cases are driven by KIT mutations and that IDRX-42 has shown activity against all key primary and secondary KIT mutations. GSK agreed on 13 January 2025 to buy IDRx for USD 1 billion upfront plus a possible USD 150 million regulatory milestone, and completed the acquisition on 24 February 2025.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: IDRx, Inc.
- HQ: Boston, MA
- Type: biotech

## Notes

- No website or founding year is recorded.

## Sources

- GSK enters agreement to acquire IDRx (6-K, 13 January 2025): https://www.sec.gov/Archives/edgar/data/1131399/000165495425000242/a0538t.htm
- GSK completes acquisition of IDRx (6-K, 24 February 2025): https://www.sec.gov/Archives/edgar/data/1131399/000165495425001815/a1769y.htm

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KIT](https://onco.cc/targets/kit/)
- drugs: [IDRX-42](https://onco.cc/drugs/idrx-42/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/idrx.json